Related Experiment Video
Updated: Jul 5, 2025

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development
Published on: March 5, 2017
Applications of Genome-Editing Technologies for Type 1 Diabetes
Rana El Nahas1,2, Mohammad Ameen Al-Aghbar1, Laura Herrero2
1Laboratory of Immunoregulation, Translational Medicine, Sidra Medicine, Doha P.O. Box 26999, Qatar.
Gene editing offers new Type 1 diabetes (T1D) treatments by guiding stem cells to produce insulin. This approach shows promise in preventing T1D development and offers a potential cure for this autoimmune disease.
Area of Science:
- Immunology
- Endocrinology
- Biotechnology
Background:
- Type 1 diabetes (T1D) is an autoimmune condition destroying insulin-producing beta cells.
- Current treatments like insulin injections manage T1D but do not offer a cure.
- Emerging therapies include immunomodulation, stem cell, and beta cell transplantation.
Purpose of the Study:
- To review T1D models and treatments utilizing gene-editing systems.
- To highlight the potential of CRISPR-Cas9 in T1D therapy.
- To explore novel approaches for T1D management and prevention.
Main Methods:
- Focus on studies employing gene-editing for T1D models and treatments.
- Investigate CRISPR-Cas9 applications for endogenous gene activation.
- Examine methods for guiding mesenchymal stem cells (MSCs) differentiation.
Main Results:
- Gene editing can reshape T-cell repertoires to prevent T1D.
- CRISPR-Cas9 shows potential for precise control of gene activation.
- MSC differentiation into insulin-producing cells is achievable via gene editing.
Conclusions:
- Gene-editing technologies present a promising avenue for T1D treatment.
- Targeted gene activation and stem cell differentiation offer novel therapeutic strategies.
- Further research in gene-editing systems could lead to effective T1D prevention and cure.
More Related Videos
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Related Concept Videos
CRISPR
What is Genetic Engineering?
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
iPS Cell Differentiation